


REMARKS

Applicants have amended the specification to insert the priority provisional application information for which this application claims benefit. Support for the amendment of the sequence GC to GA in the specification, page 5, second and third paragraphs may be found in the specification, on page 5, first and fourth paragraphs, and on page 13, third paragraph. The insertion of the verb "be" in the specification, first line of page 14, first paragraph, is an obvious grammatical amendment. Support for the amendment of the FS63 TER polymorphism in the specification, page 35, last paragraph may be found in the specification, on page 5, first and fourth paragraphs, and on page 13, third paragraph. The ABSTRACT has been added as a separate sheet, and should be inserted following the claims in the specification.

The amendments to claims 4-5, 17-19, 21-22, 25, 28, 31 and 35-38 are to eliminate multiple dependencies and to place the claims in proper format. Support for the amendment of the sequence GC to GA in claims 2 and 3 may be found in the specification, on page 5, first and fourth paragraphs, and on page 13, third paragraph. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

Date: August 16, 2005